| 29th Apr 2026 7:00 am |
RNS |
1st Quarter Results |
| 28th Apr 2026 7:00 am |
RNS |
Breztri approved in the US for asthma |
| 27th Apr 2026 7:00 am |
RNS |
Saphnelo self-administration approved in the US |
| 23rd Apr 2026 7:00 am |
RNS |
Directorate change |
| 21st Apr 2026 7:00 am |
RNS |
I CAN PhIII interim analysis met primary endpoint |
| 20th Apr 2026 7:00 am |
RNS |
Third tozorakimab positive Phase III in COPD |
| 9th Apr 2026 5:15 pm |
RNS |
Result of AGM |
| 2nd Apr 2026 7:00 am |
RNS |
Imfinzi+Imjudo improves PFS in early liver cancer |
| 1st Apr 2026 3:00 pm |
RNS |
Total Voting Rights and Admission of Shares |
| 31st Mar 2026 7:00 am |
RNS |
Efzimfotase alfa Ph3 program show positive results |
| 27th Mar 2026 7:00 am |
RNS |
Tozorakimab met OBERON/TITANIA primary endpoints |
| 20th Mar 2026 11:00 am |
RNS |
Notification of Admission of Shares |
| 16th Mar 2026 7:00 am |
RNS |
Imfinzi approved in EU for early gastric cancer |
| 16th Mar 2026 7:00 am |
RNS |
Imfinzi approved in EU for early gastric cancer |
| 10th Mar 2026 11:00 am |
RNS |
Notice of AGM |
| 10th Mar 2026 11:00 am |
RNS |
Notice of AGM |
| 6th Mar 2026 11:10 am |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2026 11:05 am |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2026 11:00 am |
RNS |
Director/PDMR Shareholding |
| 2nd Mar 2026 3:00 pm |
RNS |
Total Voting Rights |
| 26th Feb 2026 7:00 am |
RNS |
AstraZeneca prices a $2bn bond offering |
| 25th Feb 2026 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 24th Feb 2026 11:00 am |
RNS |
Annual Financial Report |
| 24th Feb 2026 7:00 am |
RNS |
Directorate change |
| 20th Feb 2026 7:00 am |
RNS |
Fixed-duration Calquence combo approved in US |
| 10th Feb 2026 7:00 am |
RNS |
Final Results |
| 3rd Feb 2026 7:00 am |
RNS |
Update on Saphnelo subcutaneous administration |
| 2nd Feb 2026 3:00 pm |
RNS |
Total Voting Rights |
| 2nd Feb 2026 7:05 am |
RNS |
Imfinzi recommended in EU for early gastric cancer |
| 2nd Feb 2026 7:00 am |
RNS |
AstraZeneca begins trading on NYSE |
| 30th Jan 2026 7:00 am |
RNS |
AstraZeneca agrees obesity and T2D deal with CSPC |
| 29th Jan 2026 9:51 am |
RNS |
AstraZeneca invests $15bn in China through 2030 |
| 20th Jan 2026 7:00 am |
RNS |
AstraZeneca to complete direct listing on NYSE |
| 8th Jan 2026 7:00 am |
RNS |
AZN new Head of Investor Relations Joris Silon |
| 2nd Jan 2026 3:00 pm |
RNS |
Total Voting Rights |
| 22nd Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 22nd Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 22nd Dec 2025 7:30 am |
RNS |
Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:30 am |
RNS |
Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:00 am |
RNS |
Update on LATIFY Phase III trial of ceralasertib |
